About this course

Learning Objectives

• Describe current updates in GLP-1 receptor agonists, including changes in availability, prescribing practices, and prevalence of use for intentional weight loss, and explain how these shifts impact patients receiving eating disorder treatment across levels of care.
• Identify and analyze the socio-cultural, systemic, and weight-stigmatizing pressures influencing patient interest in or use of GLP-1 medications, and evaluate how these forces may exacerbate eating disorder vulnerability, symptom maintenance, or recovery ambivalence.
• Assess the potential physiological, psychological, and behavioral risks associated with GLP-1 use in individuals with eating disorders, including implications for nutritional adequacy, medical stability, and treatment engagement within higher levels of care.
• Apply weight-inclusive, eating-disorder-informed clinical frameworks to collaboratively navigate GLP-1-related decision-making, interdisciplinary communication, and ethical boundary-setting while supporting recovery-oriented care.

Learning Levels

• All Levels

Course Instructor(s)

• 

  Stacy Schilter Pisano LMFT, CEDS-S

  Site Director-The Emily Program South Sound

  Stacy Schilter Pisano is a Licensed Marriage and Family Therapist and Certified Eating Disorders Specialist with nearly two decades of experience supporting individuals and families affected by body dissatisfaction and disordered eating. A passionate advocate for weight-inclusive care, Stacy is committed to educating others, reducing size discrimination, and supporting individuals in divesting from diet culture. Since 2014, she has served as the director of The Emily Program's South Sound location in Olympia, Washington, overseeing a multidisciplinary team offering PHP, IOP, OP, and FBT services. Stacy also co-developed and supervises Accanto's CARE IOP, a virtual program for Binge Eating Disorder in Minnesota, Washington, and Ohio. Stacy is an accomplished public speaker and educator who has provided multiple enriching presentations while employed by Accanto, including within company, in the community and at conferences across the nation.

• 

  M. Hilmar Wagner, MPH, RDN, LN, CD

  Clinical Education Specialist

  Hilmar Wagner is a Registered Dietitian/Nutritionist (RDN), licensed in Minnesota and Washington State. Hilmar has experience working in a variety of clinical, outpatient, community, and management settings. Hilmar joined The Emily Program in 2006 and has served in a number of clinical and management roles, both at the site, regional and organization-wide levels. He currently serves as a Clinical Outreach Specialist. In this role Hilmar has presents on a wide range of eating disorder and related nutrition topics at local, regional, and national conferences. Hilmar received his bachelor’s degree in Nutrition/Dietetics and Master’s in Public Health Nutrition from the University of Minnesota. He has worked in the field of eating disorders for the past 17 years. Hilmar has extensive experience working with clients of all eating disorder diagnoses in both individual and group settings. He has a particular interest in the application of mindfulness and body-centered, somatic approaches to the nutritional treatment of eating disorders.

References

• Celletti F, Farrar J, De Regil L. World Health Organization Guideline on the Use and Indications of Glucagon-Like Peptide-1 Therapies for the Treatment of Obesity in Adults. JAMA. 2026;335(5):434–438. doi:10.1001/jama.2025.24288
• Rubin R. Data on 3 New GLP-1 Drugs for Weight Loss That May Be Approved This Year. JAMA. 2026;335(8):653–655. doi:10.1001/jama.2026.0287
• Haoyang Guo, Juan Yang, Jihan Huang, Ling Xu, Yinghua Lv, Yexuan Wang, Jiyuan Ren, Yulin Feng, Qingshan Zheng, Lujin Li, Comparative efficacy and safety of GLP-1 receptor agonists for weight reduction: A model-based meta-analysis of placebo-controlled trials. Obesity Pillars, Volume 13,2025
• Gigliotti L, Warshaw H, Evert A, Dawkins C, Schwartz J, Susie C, Kushner R, Subramanian S, Handu D, Rozga M. Incretin-Based Therapies and Lifestyle Interventions: The Evolving Role of Registered Dietitian Nutritionists in Obesity Care. J Acad Nutr Diet. 2025 Mar;125(3):408-421. doi: 10.1016/j.jand.2024.10.023. Epub 2024 Nov 7. PMID: 39521378.
• Puhl RM, Heuer CA. Obesity stigma: important considerations for public health. Am J Public Health. 2010 Jun;100(6):1019-28. doi: 10.2105/AJPH.2009.159491. Epub 2010 Jan 14. PMID: 20075322; PMCID: PMC2866597.
• Allison, KC, Chao, AM, Bruzas, MB, et al. A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder. Obes Sci Pract. 2023; 9(2): 127-136. https://doi.org/10.1002/osp4.619.
• Bartel, S., McElroy, S. L., Levangie, D., & Keshen, A. (2024). Use of glucagon-like peptide-1 receptor agonists in eating disorder populations. The International journal of eating disorders, 57(2), 286–293. https://doi.org/10.1002/eat.24109.
• Beach EC, De Jesus O. (2023). Ileus. Treasure Island (FL): StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK558937/.
• Da Porto, A., Casarsa, V., Colussi, G., Catena, C., Cavarape, A., & Sechi, L. (2020). Dulaglutide reduces binge episodes in type 2 diabetic patients with binge eating disorder: A pilot study. Diabetes & metabolic syndrome, 14(4), 289–292. https://doi.org/10.1016/j.dsx.2020.03.009.
• DiLonardo, M. J., & Dansinger, M. (2023). Hypoglycemia (low blood sugar): Symptoms, causes, treatment, Diet. WebMD. https://www.webmd.com/diabetes/hypoglycemia-overview.
• Dennis, Kim. (2025). GLP-1 Receptor Agonists and Eating Disorders. NEDA. https://www.nationaleatingdisorders.org/glp-and-eating-disorders/
• Richards, J., Bang, N., Ratliff, E. L., Paszkowiak, M. A., Khorgami, Z., Khalsa, S. S., & Simmons, W. K. (2023). Successful treatment of binge eating disorder with the GLP-1 agonist semaglutide: A retrospective cohort study. Obesity pillars, 7, 100080. https://doi.org/10.1016/j.obpill.2023.100080.
• Robert, S. A., Rohana, A. G., Shah, S. A., Chinna, K., Wan Mohamud, W. N., & Kamaruddin, N. A. (2015). Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot study. Obesity research & clinical practice, 9(3), 301–304. https://www.sciencedirect.com/science/article/abs/pii/S1871403X1500037X?via%3Dihub.